Table 3.

Treatment-emergent kidney-related adverse events during the entire double-blind treatment period

Adverse EventGlimepiride (n=482), n (%)Canagliflozin 100 mg (n=483), n (%)Canagliflozin 300 mg (n=485), n (%)
Total number of subjects with kidney-related adverse events16 (3.3)15 (3.1)16 (3.3)
Blood creatinine increased5 (1.0)2 (0.4)1 (0.2)
GFR decreased10 (2.1)11 (2.3)10 (2.1)
Renal failure01 (0.2)3 (0.6)
Renal failure acute01 (0.2)0
Renal impairment3 (0.6)03 (0.6)
  • All adverse events are investigator-reported events without adjudication by a separate committee.